Pathological events during eariy brain development are believed to hold the key to the emergence of schizophrenia (SZ) in adulthood. Deficits in memory, attention and executive function, i.e. core domains of the psychopathology of SZ, might be causally related to dysfunctional glutamatergic and nicotinergic transmission. Kynurenine acid (KYNA), an astrocytic metabolite ofthe kynurenine pathway of tryptophan degradation, is an endogenous inhibitor of a7nACh and NMDA receptors in the brain and has been implicated in the pathology of SZ. Studies using cerebrospinal fluid (CSF) or post-mortem brain tissue of patients with SZ suggest that an excess of KYNA might play a causative role in the disease. As an endogenous antagonist at a7nAChRs and NMDARs, which are both critically involved in cognitive functions, increased KYNA levels in the brain might be especially involved in the cognitive deficits that are seen in individuals with SZ. The connection between KYNA and SZ may have a developmental dimension as several ofthe risk factors associated with SZ, including prenatal infections, result in the activation of a cytokine-responsive enzyme that catalyzes an increase in the formation of kynurenine, the direct bioprecursor of KYNA. The proposed project is based on recent studies showing that elevating brain KYNA from embryonic day (ED) 15 to postnatal day (PD) 21 results in impaired cognitive function in the adult offspring. The planned experiments are centered around the fundamentally new concept, supported by preliminary data included in this proposal, that elevating KYNA during the prenatal developmental period alone may serve as a model to study the etiology of cognitive dysfunction in SZ. The central hypothesis of this proposal is that elevated KYNA formation during prenatal development, produced from its bioprecursor kynurenine, influences the development ofthe brain and, as a result, alters kynurenine pathway dynamics, extracellular glutamate levels, and modulates hippocampal-mediated cognitive behavior in adulthood. It follows, and will be tested here, that inhibition of KYNA synthesis is a valuable therapeutic strategy to combat cognitive deficits in SZ.

Public Health Relevance

Cognitive dysfunctions are a core domain of the psychopathology of schizophrenia (SZ), a debilitating disorder affecting ~ 1 % ofthe population. The proposed work is designed to provide new insights into the role of kynurenic acid (KYNA), a neuroactive compound that is elevated in the brain of individuals with SZ, in cognition, and examine inhibition of KYNA formation as a novel strategy to overcome cognitive dysfunction.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center (P50)
Project #
1P50MH103222-01
Application #
8816212
Study Section
Special Emphasis Panel (ZMH1-ERB-L (01))
Project Start
Project End
Budget Start
2014-05-09
Budget End
2015-04-30
Support Year
1
Fiscal Year
2014
Total Cost
$444,635
Indirect Cost
$146,257
Name
University of Maryland Baltimore
Department
Type
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Albrecht, Matthew A; Vaughn, Chloe N; Erickson, Molly A et al. (2018) Time and frequency dependent changes in resting state EEG functional connectivity following lipopolysaccharide challenge in rats. PLoS One 13:e0206985
Du, Xiaoming; Hong, L Elliot (2018) Test-retest reliability of short-interval intracortical inhibition and intracortical facilitation in patients with schizophrenia. Psychiatry Res 267:575-581
Du, Xiaoming; Rowland, Laura M; Summerfelt, Ann et al. (2018) TMS evoked N100 reflects local GABA and glutamate balance. Brain Stimul 11:1071-1079
Du, Xiaoming; Rowland, Laura M; Summerfelt, Ann et al. (2018) Cerebellar-Stimulation Evoked Prefrontal Electrical Synchrony Is Modulated by GABA. Cerebellum :
Song, Chang; Clark, Sarah M; Vaughn, Chloe N et al. (2018) Quantitative Analysis of Kynurenine Aminotransferase II in the Adult Rat Brain Reveals High Expression in Proliferative Zones and Corpus Callosum. Neuroscience 369:1-14
Chiappelli, Joshua; Notarangelo, Francesca M; Pocivavsek, Ana et al. (2018) Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia. Neuropsychopharmacology 43:1675-1680
van Erp, Theo G M; Walton, Esther; Hibar, Derrek P et al. (2018) Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biol Psychiatry 84:644-654
Pocivavsek, Ana; Rowland, Laura M (2018) Basic Neuroscience Illuminates Causal Relationship Between Sleep and Memory: Translating to Schizophrenia. Schizophr Bull 44:7-14
Hahn, Britta; Reneski, Carolyn H; Pocivavsek, Ana et al. (2018) Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood. Psychopharmacology (Berl) 235:651-661
Kelly, Deanna L; Li, Xin; Kilday, Catherine et al. (2018) Increased circulating regulatory T cells in medicated people with schizophrenia. Psychiatry Res 269:517-523

Showing the most recent 10 out of 78 publications